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T.lymphocyte subsets in nephrotic syndrome. T-lymphocyte subsets
when measured in steroid responsive nephrotic syndrome (SRNS) have
demonstrated significant variance from normal values. T-cell subsets
were studied by using two-color flow cytometric analysis in 32 children
(9.2 5 years of age) with SRNS. The children were divided into four
groups: a) SRNS in acute relapse, on prednisone; b) SRNS in acute
relapse, off prednisone; C) SRNS in long-term remission, off prednisone
(nephrotic controls); d) patients in remission on long-term prednisone
therapy; and e) 15 age-matched normal controls. Children suffering an
acute relapse of SRNS showed an increase in Leu2a+/DR+ (CD8)
activated lymphocytes (P < 0.05), a decrease in Leu4a+ total T-lym-
phocytes (P = 0.01) and a decrease in Leu3a+ (CD4) helper T-cells (P
< 0.05) when compared to normal controls and nephrotic controls.
Though some subset changes may represent a prednisone effect and the
functional role of these lymphocytes in the disease process is unknown,
this study provides additional evidence to support a role for abnormal
T-cell subsets in the etiology of SRNS.
Steroid responsive nephrotic syndrome (SRNS) is a glomer-
ular disease characterized by proteinuria, hypoalbuminemia,
generalized edema, and hypercholesterolemia. The etiology of
SRNS remains unclear, but ample reason exists to suspect a
role for abnormal lymphocyte populations and function. The
onset of the nephrotic syndrome is often associated with prior
upper respiratory tract infections and other immunogenic stim-
uli such as bee stings or contact dermatitis [1—31. Remission of
SRNS has been known to be associated with measles infection
and Hodgkins's disease [4, 5], both of which cause a depression
of cell-mediated immunity.
Shaihoub first hypothesized the existence of a circulating
basement membrane-damaging lymphokine produced by an
abnormal lymphocyte subset in SRNS patients [4, 61. More
specific evidence for lymphocyte involvement includes the
finding that T-lymphocytes from patients with symptomatic
SRNS demonstrate markedly reduced responses to mitogenic
stimulation, an effect which may be related to a circulating
humoral factor or lymphokine [6—10]. One previous study using
monoclonal antibodies (MAb's) to study lymphocyte subpop-
ulations found no significant differences between SRNS pa-
tients and normal control [11]. However, Kerpen, et al earlier
demonstrated that SRNS patients had an abnormal lymphocyte
Received for publication August 28, 1989
and in revised form June 6, 1991
Accepted for publication June 11, 1991
© 1991 by the International Society of Nephrology
population bearing surface markers characteristic of both B and
T lymphocytes [12]. Using the relatively new technique of flow
cytometry, one can more directly quantitate and examine
lymphocyte subsets. We used flow cytometric analysis to study
T-lymphocyte subsets in 32 children with SRNS. The use of
two-color flow cytometry allowed us to distinguish activated
from non-activated T-lymphocytes. Using this methodology,
we found distinct abnormalities in the T-lymphocyte subsets of
children with relapsing SRNS.
Methods
Patient population
Thirty-two children with steroid responsive nephrotic syn-
drome were studied, all of whom are followed in the Pediatric
Renal Clinic at Arkansas Children's Hospital (ACH). The
diagnosis of SRNS was made from clinical responsiveness to
steroids and was not confirmed by renal biopsy. These patients
ranged in age from seventeen months to 18 years (mean 9.2
5.2 years). None of the patients were taking or had been given
immunosuppressive drugs (such as cyclophosphamide). For
study purposes, the SRNS patients were divided into one of
three subgroups: (la) SRNS on prednisone therapy but suf-
fering an acute nephrotic relapse, defined by sudden onset of
proteinuria of three days' duration with 3 + protein by urine
dipstick; (ib) SRNS patients not receiving prednisone and
suffering the same symptoms as Group la, including two
patients at initial diagnosis; (2) SRNS in long-term remission,
defined as being free of both prednisone therapy and proteinuria
for at least six months; (3) patients whose disease was in a state
of remission maintained by prednisone therapy for at least six
months. Thirteen patients were suffering acute relapse symp-
toms, six in the prednisone-free group and seven receiving
prednisone. Eight patients were in long-term untreated remis-
sion, and the remaining eleven were in a prednisone-maintained
remission. Fifteen normal control patients also participated in
the study. These children were enlisted from among outpatients
seen at the Children's Care Center, ACH or from children
having elective surgery. Only those patients who demonstrated
no reasons for suspecting immunological abnormalities or renal
dysfunction were selected as normal controls. An attempt was
made to match normal patients to the nephrotic patients by age
and sex. These normal control patients ranged in age from ten
months to fifteen years (mean 10.1 + 4.8 years). The patients in
long-term untreated remission served as a nephrotic control
group. Twenty-one females and twenty-four males participated.
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Informed consent was obtained from all patients and controls
(Table 1).
Sample collection and treatment
Peripheral venous blood was collected and treated with a
battery of monoclonal antibodies for flow cytometric analysis.
Blood was collected in acid citrate dextrose (ACD) tubes and
was submitted to monoclonal antibody staining within 48 hours
of collection. In most, but not all, an additional sample was
obtained for white blood cells (WBC) counts performed by a
Coulter Counter and peripheral blood smears.
Monoclonal antibodies (Becton-Dickinson Immunochemis-
try, Mountain View, California, USA) were labelled with either
fluorescein isothiocyanate (FITC) or phycoerythrin (PE), ex-
cept for the anti-Leu4a!HLA-DR Simultest reagent, which
contains both FITC-conjugated anti-Leu4a and PE-conjugated
anti-HLA-DR. The MAb's used are defined as follows: anti-
Leu4a/HLA-DR Simultest (CD3, total T-lymphocytes); anti-
Leu3a (CD4, T-helper); anti-Leu2a (CD8, T-suppressor and
cytotoxic); anti-HLA-DR (B-lymphocytes and activated T-lym-
phocytes), anti-transferrin receptor (proliferating T-lympho-
cytes), and anti-1L2 receptor (activated T-lymphocytes).
An aliquot of each sample was stained with both an anti-T cell
(CD3, CD4, or CD8) and an activation marker for the determi-
nation of the percentage of those T-cells that were activated as
evidence by staining with that particular activation marker.
The cells were stained using standard whole blood staining
techniques as outlined in the package insert. Briefly, the cells
were incubated for 30 minutes at room temperature in the dark
and the RBC's then lysed with FACS Lysing Solution (Becton
Dickinson). The cells were then washed with PBS and fixed
with 1% paraformaldehyde. The fixed cells were stored at 4°C
and analyzed within 24 hours of staining. Cells were analyzed
with a Coulter EPICS 751 flow cytometer (Coulter Corp.,
EPICS Division, Hialeah, Florida, USA). Parametrized two-
color data was collected on the samples after gating on the
lymphocyte population using forward and 90° angle light scat-
ter. The threshold for positivity was determined by utilizing
isotypic IgG PE and/or FITC as a negative control peak with 1%
positive staining occurring outside this peak interval. Percent-
ages of double and single-stained cells were determined using
Coulter Quatstats analysis program, on the EPICS 751. This
program allows division of a two-parameter histogram into four
quadrants, as shown in the sample histogram (Fig. 1). Un-
stained, or negative cells are boxed into quadrant one and stain
with PE only (the activation marker), while cells in quadrant
four stain with FITC only (the anti-T-cell). Those cells falling in
quadrant two are the double-stained cells positive for both
FITC an PE. The percent double positive activated lympho-
cytes and single positive anti-T-cells but were used to calculate
absolute lymphocyte counts for each T-cell subset.
Statistical methods
The mean and standard deviation were determined for each
variable in all patient groups. Significance of differences were
determined by analysis of variance (ANOVA).
Results
The percent of each T-cell subset obtained by our methodol-
ogy is given for each diagnostic group in Table 2. Absolute
lymphocyte counts for each group are given in Table 3. Not
every patient received a complete blood count (CBC) at the
time of flow cytometry, therefore, the number of patients with
absolute lymphocyte counts is slightly smaller than the total
patient population. Patients in acute untreated relapse, defined
by 3 + or greater proteinuria, demonstrated a significant de-
crease in the percentage of total T-cells or Leu4a+ cells, when
compared with normal controls (P < 0.05). Total lymphocyte
counts were also decreased in this group (Fig. 2). There were no
differences in percentile or absolute lymphocyte counts be-
tween the normal, non-nephrotic control patients and the pa-
tients who were in long-term, untreated remission from their
proteinuria (nephrotic controls). These two groups seemed
similar in all the aspects investigated in this paper.
There was an increase in the percent of activated
Leu2a+DR+ cells (Fig. 3) in children with acute proteinuria
when compared to those with minimal proteinuria, that is, those
patients treated and untreated in remission for their nephrotic
syndrome (P < 0.05).
The percentage and absolute numbers of Leu3a+, or total
T-helper cells, was found to be significantly decreased in the
patients in relapse, both treated and untreated, when compared
to normal controls and nephrotic controls (P < 0.05). This
decrease in Leu3a+ cells may be an effect due to prednisone.
Sex
No. pts. Age Male Female
Normal control 15 7.9 5.1 8 7
Untreated relapse 6 7.8 4,1 3 3
Treated relapse 7 8.0 4.1 2 5
Untreated remission 11 9.6 3.2 6 5
Treated remission 8 8.9 3.5 5 3
3
Quadrant statistics
Fig. 1. Quatstat for a representative double-stained sample.
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However, a comparison of Leu3a+ values of normal controls
with those of relapsing patients not on prednisone also showed
a significant difference (Fig. 4). The demonstrated decrease in
the Leu3 + subset is probably largely responsible for the de-
crease in total T-cells (Leu4a+ cells) seen in patients with acute
proteinuria. More evidence that the decreased numbers of
Leu3a+ cells was due to prednisone treatment can be drawn
from a comparison of patients in remission maintained by
prednisone with untreated patients in long-term remission (ne-
phrotic controls), all of whom had been off prednisone for at
least six months. Compared to those in a long prednisone-free
remission, patients in prednisone-maintained remission demon-
strated a significant decrease in Leu3a+ cells (P < 0.05).
Leu3a+DR+ cells were neither significantly increased nor
decreased among the groups. Comparison of the group in acute
relapse to the group maintained in remission by prednisone
yielded no significant values for any of the variables. Staining
with anti-transferrin receptor (mean 1.8 2.7) and anti-1L2
receptor (mean 0.3 0.3) to test for lymphocyte activation
yielded no significant differences between groups.
Discussion
Both CD4 (Leu3a+) and CD8 (Leu2a+) cells seem to dem-
onstrate abnormalities in SRNS. CD4 cells comprise the
T-helper functional subset, important in the initiation of an
immune response. CD8 lymphocytes are more diverse in func-
tion. These cells can posses either suppressor activity, crucial
for regulation of an immune response, or cytotoxic activity,
known to be important in tumor immunity and in viral infec-
tions.
Patients in acute relapse demonstrated an increase in the
percentage of Leu2a+DR+ cells and a significant decrease in
the percentage and absolute numbers of Leu3a+ cells when
compared to normal controls. The decrease in Leu3a+ cells in
these patients is probably due to their prednisone therapy, since
a comparison of Leu3a+ values in controls and relapse patients
free of prednisone yielded no significant differences. Also,
patients maintained in remission by prednisone had lower
Leu3a+ values than patients enjoying a long-term remission
free of prednisone treatment. It is important to note, however,
that the increases in Leu2a+DR+ cells in relapsing patients
cannot be merely an artifact secondary to the prednisone-
induced drop in the Leu3a+ percentage because the increase in
Leu2a+/DR+ cells was still significant in the patients not on
prednisone therapy at time of relapse.
T-cells which have been activated by IL-2 express surface
antigens which are not seen on non-activated T-cells. These
activation markers include HLA-DR, a receptor for transferrin,
and a receptor for IL-2. Transferrin and IL-2 are usually
elevated in an inflammatory reaction. The absence of changes in
transferrin or IL-2 receptors during acute episodes of nephrotic
syndrome or during prednisone therapy woutd suggest the
Table 2. Percent T-lymphocyte subsets in children with SRNS
No. pts. Leu4+ Leu4+DR+ Leu3+ Leu3+DR+ Leu2+ Leu2+DR+
Normal control 15 61.3 9.9 1.5 0.8
Untreated relapse 6 49.1 20.5a 1.6 0.7
Treated relapse 7 63.5 16.1 2.3 1.8
Treated remission 11 52.6 13.3 1.5 0.9
Untreated remission (nephrotic controls) 8 70.1 49 1.6 0.7
39.6 8.6 0.9 0.5
29.3 13.7" 1.1 2.0
35.2 9•8b 1.7 1.5
26.8 110b 0.8 0.6
40.1 6.5 0.9 0.4
22.0 7.7
21.5 11.3
18.3 15.4
20.9 7.6
27.4 4.0
0.78 0.42
1.6 2.l'
2.1 2.0c
0.75 0.41
1.0 0.1
a P < 0.05 compared to normal controlsb p < 0.05 compared to normal controls or to untreated remission
P < 0.05 compared to normal controls, treated or untreated remission
Table 3. T-lymphocyte subset in children with SRNS: Absolute cell counts (cells/mm3)
Total
No. pts. lymphocytes Leu4a+DR+ Leu3aDR+ Leu2aDR+
Normal control 15 4409 2889 58 37 36 25 27 23
Untreated relapse 4 2270 l44 46 62 18 15b 33 45
Treated relapse
Treated remission
5
8
2590
2539
1056
880
37
42
29
40
37
23
56
22"
26 13
22 13
Untreated remission (nephrotic control) 4 4192 194 84 50 46 27 50 40
a p < 0.05 compared to normal control or to treated remissionb P < 0.05 compared to treated remission
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Fig. 2. Percent cells Leu4a+DR+. *P = 0.01 for B vs. E.
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absence of inflammatory reactions associated with these mark-
ers.
A two-color flow cytometry study of lymphocyte abnormal-
ities in SRNS performed by Yamada et a! reported a similar
decrease in the percentage of Leu3a+ cells in patients receiving
prednisolone (PSL) coupled with an increase in the percentage
of Leu2a+ cells [131. The two-color approach used by Yama-
da's group did not assay lymphocyte activation. Rather, they
used second markers to more specifically define subsets, such
as suppressor-inducer cells (Leu3a+Leu8+) and killer T cells
(Leu2a+LeulS+). Interestingly, in nephrotic patients not re-
ceiving prednisolone, Yamada's group found no significant
difference from normal control values for any of the 1-lympho-
cyte subsets. Presently there seems to be ample reason to
suspect a role for abnormal lymphocyte function in the etiology
and pathogenesis of SRNS in children. Yamada's findings and
the results of our study lend credence to the basic hypothesis
that an abnormality of T-lymphocyte subsets and function may
be involved in the pathogenesis of SRNS, though the data is
somewhat inconsistent. More convincing evidence might be
obtained from a prospective longitudinal study of patients with
SRNS. If an abnormal 1-cell subset is consistently identified, it
should be further assayed for functional activity and production
of Shaihoub's hypothesized lymphokine [4, 9].
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